INNOVENT BIOLOGICS, INC.

Analyst Reco. Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Delayed Hong Kong S.E. Other stock markets 01:39:31 2024-05-29 am EDT			5-day change	1st Jan Change
35.7 ^HKD	-2.99%		-5.92%	-16.37%

May. 28	Innovent Biologics, Inc. Announces Picankibart Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA	CI
May. 21	Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy	Feb. 26	MT
Nomura Adjusts Innovent Biologics’ Price Target to HK$54.51 From HK$45.73, Keeps at Buy	Nov. 06	MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.73 From SG$54.72, Keeps at Buy	23-07-20	MT
Nomura Adjusts Innovent Biologics' Price Target to HK$54.72 From HK$45.44, Keeps at Buy	23-02-06	MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.44 From HK$45.38, Keeps at Buy	22-08-26	MT
UBS Adjusts Innovent Biologics' Price Target to HK$42 From HK$39.30, Keeps at Buy	22-08-09	MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.38 From HK$43.75, Keeps at Buy	22-08-05	MT
Hong Kong stocks down as tech shares slide ahead of Fed rate decision	22-05-04	RE
Nomura Adjusts Innovent Biologics' Price Target to HK$43.75 From HK$49.41, Keeps at Buy	22-04-29	MT
UBS Adjusts Innovent Biologics' Price Target to HK$43 From HK$60, Keeps at Buy	22-04-08	MT
Nomura Adjusts Innovent Biologics' Price Target to HK$49.41 From HK$58.18, Keeps at Buy	22-03-31	MT
Nomura Adjusts Innovent Biologics Price Target to HK$58.18 From HK$92.73, Keeps at Buy	22-02-14	MT
Tech stocks drag Hong Kong shares lower on U.S. rate hike concerns	22-02-11	RE
INNOVENT BIOLOGICS : Nomura Adjusts Innovent's Price Target to HK$113.4 From HK$66.3, Keeps at Buy	21-02-04	MT
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas	20-12-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer